BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 30746599)

  • 1. Evaluation of whole-body tumor burden with
    Brito AET; Mourato FA; de Oliveira RPM; Leal ALG; Filho PJA; de Filho JLL
    Ann Nucl Med; 2019 May; 33(5):344-350. PubMed ID: 30746599
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Schmidkonz C; Cordes M; Schmidt D; Bäuerle T; Goetz TI; Beck M; Prante O; Cavallaro A; Uder M; Wullich B; Goebell P; Kuwert T; Ritt P
    Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1862-1872. PubMed ID: 29725716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients.
    Schmidkonz C; Cordes M; Goetz TI; Prante O; Kuwert T; Ritt P; Uder M; Wullich B; Goebell P; Bäuerle T
    Ann Nucl Med; 2019 Oct; 33(10):766-775. PubMed ID: 31338731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initial Experience with Volumetric
    Schmuck S; von Klot CA; Henkenberens C; Sohns JM; Christiansen H; Wester HJ; Ross TL; Bengel FM; Derlin T
    J Nucl Med; 2017 Dec; 58(12):1962-1968. PubMed ID: 28522740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. (68)Ga-PSMA-11 dynamic PET/CT imaging in biochemical relapse of prostate cancer.
    Sachpekidis C; Eder M; Kopka K; Mier W; Hadaschik BA; Haberkorn U; Dimitrakopoulou-Strauss A
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1288-99. PubMed ID: 26753602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Semi-automatic evaluation of baseline whole-body tumor burden as an imaging biomarker of
    Zou Q; Jiao J; Zou MH; Li MZ; Yang T; Xu L; Zhang Y
    Abdom Radiol (NY); 2020 Dec; 45(12):4202-4213. PubMed ID: 32948911
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Calais J; Czernin J; Cao M; Kishan AU; Hegde JV; Shaverdian N; Sandler K; Chu FI; King CR; Steinberg ML; Rauscher I; Schmidt-Hegemann NS; Poeppel T; Hetkamp P; Ceci F; Herrmann K; Fendler WP; Eiber M; Nickols NG
    J Nucl Med; 2018 Feb; 59(2):230-237. PubMed ID: 29123013
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Ceci F; Castellucci P; Graziani T; Farolfi A; Fonti C; Lodi F; Fanti S
    Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):31-39. PubMed ID: 30350010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection Rate and Localization of Prostate Cancer Recurrence Using
    Kranzbühler B; Müller J; Becker AS; Garcia Schüler HI; Muehlematter U; Fankhauser CD; Kedzia S; Guckenberger M; Kaufmann PA; Eberli D; Burger IA
    J Nucl Med; 2020 Feb; 61(2):194-201. PubMed ID: 31375566
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Farolfi A; Ceci F; Castellucci P; Graziani T; Siepe G; Lambertini A; Schiavina R; Lodi F; Morganti AG; Fanti S
    Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):11-19. PubMed ID: 29905907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiphasic
    Beheshti M; Manafi-Farid R; Geinitz H; Vali R; Loidl W; Mottaghy FM; Langsteger W
    J Nucl Med; 2020 Oct; 61(10):1484-1490. PubMed ID: 32060214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathological predictors of positive
    Aydin AM; Haberal B; Artykov M; Bilen CY; Yazici S
    Ann Nucl Med; 2019 May; 33(5):326-332. PubMed ID: 30778860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection Efficacy of Hybrid
    Einspieler I; Rauscher I; Düwel C; Krönke M; Rischpler C; Habl G; Dewes S; Ott A; Wester HJ; Schwaiger M; Maurer T; Eiber M
    J Nucl Med; 2017 Jul; 58(7):1081-1087. PubMed ID: 28209912
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Uprimny C; Kroiss AS; Decristoforo C; Fritz J; von Guggenberg E; Kendler D; Scarpa L; di Santo G; Roig LG; Maffey-Steffan J; Horninger W; Virgolini IJ
    Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):941-949. PubMed ID: 28138747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [
    Xie Y; Li C; Zhang L; Zang S; Yu F; Wang S; Wang F
    Nan Fang Yi Ke Da Xue Xue Bao; 2022 Aug; 42(8):1143-1148. PubMed ID: 36073212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Total-Body
    Pomykala KL; Czernin J; Grogan TR; Armstrong WR; Williams J; Calais J
    J Nucl Med; 2020 Mar; 61(3):405-411. PubMed ID: 31541035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective correlation of
    Onal C; Torun N; Oymak E; Guler OC; Reyhan M; Yapar AF
    Ann Nucl Med; 2020 Jun; 34(6):388-396. PubMed ID: 32221791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of 68Ga-PSMA-I&T PET/CT in the pretreatment staging of primary prostate cancer.
    Meyrick DP; Asokendaran M; Skelly LA; Lenzo NP; Henderson A
    Nucl Med Commun; 2017 Nov; 38(11):956-963. PubMed ID: 28922335
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
    Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.